Showing 5331-5340 of 9772 results for "".
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor
- Neutrogena Announces New "Heroes of Skin Health Equity" Initiativehttps://practicaldermatology.com/news/neutrogena-announces-new-heroes-of-skin-health-equity-initiative/2461057/Neutrogena is launching its new Heroes of Skin Health Equity initiative, the brand’s latest effort aimed at closing the gap to skin health equity for those with Black and brown skin. The brand will publicly recognize the work of individuals who are striving to make
- Desert Harvest's Aloe Glide Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/desert-harvests-aloe-glide-receives-nea-seal-of-acceptance/2461056/Desert Harvest’s Aloe Glide has received the National Eczema Association (NEA) Seal of Acceptance, making it the first sexual lubricant to earn this seal. The NEA Seal appears on products approved by the association to help consumers identify and choose products that are suitable
- Light Therapy Fast-tracks Healing of Skin Damage from Brachytherapyhttps://practicaldermatology.com/news/light-therapy-fast-tracks-healing-of-skin-damage-from-brachytherapy/2461055/Light therapy may accelerate the healing of skin damage from radiation therapy by up to 50 percent, according to a recent University at Buffalo-led study. Photobiomodulation – a form of low-dose light therapy –lowered the severity of skin damage from radionecrosis, reduced i
- Allergan Aesthetics Announces Open Casting Call for BOTOX Cosmetichttps://practicaldermatology.com/news/allergan-aesthetics-announces-open-casting-call-for-botox-cosmetic/2461051/Allergan Aesthetics is hosting an open casting call seeking people who would like to share their BOTOX Cosmetic Story. Building on the success of the original
- Vial Connects with Advisory Board at 2022 Maui Dermatology Conferencehttps://practicaldermatology.com/news/vial-connects-with-advisory-board-at-2022-maui-dermatology-conference/2461050/Vial, in conjunction with the 2022 Maui Dermatology Conference, is hosting an Advisory Board co-hosted by Leon Kircik, MD, FAAD. Dr. Kircik and Vial, along with leading research sites, will discuss and collaborate on how Vial can continue to help grow dermatology research sites and tackle the big
- Survey Reveals Impact of AGA on Affected Men, Interest in New Therapieshttps://practicaldermatology.com/news/survey-reveals-impact-of-aga-on-affected-men-interest-in-new-therapies/2461046/Nearly two-thirds (64%) of men with androgentic alopecia (AGA) say the condition has a negative affect on their lives, yet more than half (56%) have never sought treatment for the condition, results of a survey show. Findings from the survey, conducted on behalf of
- Scientis: Mikki Bey Crawford Named US VP and General Manager, Aesthetic Dermatologyhttps://practicaldermatology.com/news/scientis-mikki-bey-crawford-named-us-vp-and-general-manager-aesthetic-dermatology/2461045/Mikki Bey Crawford is now US Vice President and General Manager, Aesthetic Dermatology for Scientis. In her new role, she will lead the sales and marketing teams to accelerate the growth of Cyspera® in the US. "We are so pleased t
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof